Stocks · News reference
Molecular Partners Q2 EPS $(0.89) Misses $(0.45) Estimate
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.45) by 95.56 percent. This is a 31.34 percent decrease over losses of $(0.67) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 25, 2026, 10:15 AM
- Checked
- Aug 25, 2026, 10:15 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Molecular Partners Reports Nine Active Trial Sites And Ongoing Treatment In Phase 2 MP0317 Cholangiocarcinoma Study, With Data Update Expected In 2027 And Completion In 2028
Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoingData update expected in 2027, with trial completion in 2028Trial-in-progress poster to be
Read original at benzingaMolecular Partners Highlights Multispecific Radio-DARPins Formatted As Bispecific Or 2-In-1 DuoDARPin To Address Tumor Heterogeneity
Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacyPresentation outlines Radio-DARPins’ ability to match target and disease biology for
Read original at benzinga